alpha-hydroxyglutarate has been researched along with Neoplasms in 53 studies
2-hydroxyglutarate : A dicarboxylic acid anion obtained by deprotonation of at least one of the carboxy groups of 2-hydroxyglutaric acid.
2-hydroxyglutaric acid : A 2-hydroxydicarboxylic acid that is glutaric acid in which one hydrogen alpha- to a carboxylic acid group is substituted by a hydroxy group.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " c-MYC also regulates glutamine metabolism and drives progression of asymptomatic precursor plasma cell (PC) malignancies to symptomatic multiple myeloma (MM)." | 3.88 | Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies. ( Dutta, T; Ghosh, T; Gonsalves, WI; Hitosugi, T; Jevremovic, D; Kumar, SK; Nair, KS; Petterson, XM; Ramakrishnan, V; Sakrikar, D; Wellik, L, 2018) |
| "Ivosidenib (AG-120) is a targeted mutant IDH1 inhibitor under evaluation in a phase 1 dose escalation and expansion study of IDH1-mutant advanced solid tumors including cholangiocarcinoma, chondrosarcoma, and glioma." | 2.94 | Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. ( Agresta, S; Dai, D; Fan, B; Gliser, C; Goyal, L; Jiang, L; Liu, G; Lowery, MA; Manyak, E; Mellinghoff, IK; Nimkar, T; Pandya, SS; Prahl Judge, M; Tap, WD; Wen, PY; Yang, H, 2020) |
| " We explored the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of ivosidenib in these populations." | 2.94 | Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. ( Agresta, S; Dai, D; Fan, B; Gliser, C; Goyal, L; Jiang, L; Liu, G; Lowery, MA; Manyak, E; Mellinghoff, IK; Nimkar, T; Pandya, SS; Prahl Judge, M; Tap, WD; Wen, PY; Yang, H, 2020) |
| "It is now known that cancer cells remodel their metabolic network to support biogenesis, caused by or resulting in the dysregulation of various metabolites." | 2.66 | Metabolite sensing and signaling in cancer. ( Lei, QY; Li, JT; Qu, J; Wang, YP; Yin, M, 2020) |
| "Abnormal metabolism is common in cancer cells and often correlates with mutations in genes encoding for enzymes involved in small-molecule metabolism." | 2.66 | Isocitrate dehydrogenase variants in cancer - Cellular consequences and therapeutic opportunities. ( Cadoux-Hudson, T; Liu, S; Schofield, CJ, 2020) |
| "Altered metabolism in cancer was first discovered by Otto Warburg early last century." | 2.49 | Metabolic alteration in tumorigenesis. ( Guan, K; Xiong, Y; Yang, H, 2013) |
| "Breast tumors with high 2HG exhibit enhanced heterogeneity with undifferentiated epigenomic signatures linked to adverse prognosis." | 1.72 | 2-Hydroxyglutarate destabilizes chromatin regulatory landscape and lineage fidelity to promote cellular heterogeneity. ( Chen, M; Huang, TH; Kirma, NB; Kusi, M; Lin, CL; Lin, LL; Lopez, A; Lucio, ND; Mitsuya, K; Ruan, J; Wang, CM; Zand, M, 2022) |
| "Many types of cancer feature TP53 mutations with oncogenic properties." | 1.72 | Malic enzyme 2 maintains protein stability of mutant p53 through 2-hydroxyglutarate. ( Cheng, J; Du, W; Geng, C; Jiang, P; Mao, Y; Wang, W; Wu, J; Yao, P; Zhao, M, 2022) |
| " Here we developed a strategy by chiral derivatization combined with liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) analysis for highly sensitive determination of D-2HG and L-2HG enantiomers." | 1.42 | Sensitive Determination of Onco-metabolites of D- and L-2-hydroxyglutarate Enantiomers by Chiral Derivatization Combined with Liquid Chromatography/Mass Spectrometry Analysis. ( Cheng, QY; Ci, W; Feng, YQ; Huang, W; Ma, Q; Xiong, J; Yuan, BF, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 35 (66.04) | 24.3611 |
| 2020's | 18 (33.96) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, X | 1 |
| Yamaguchi, K | 1 |
| Takane, K | 1 |
| Zhu, C | 1 |
| Hirata, M | 1 |
| Hikiba, Y | 1 |
| Maeda, S | 1 |
| Furukawa, Y | 1 |
| Ikenoue, T | 1 |
| Xiao, D | 1 |
| Zhang, W | 1 |
| Guo, X | 1 |
| Liu, Y | 2 |
| Hu, C | 1 |
| Guo, S | 1 |
| Kang, Z | 1 |
| Xu, X | 1 |
| Ma, C | 1 |
| Gao, C | 1 |
| Xu, P | 1 |
| Yang, Q | 1 |
| Hao, J | 1 |
| Chi, M | 1 |
| Wang, Y | 1 |
| Li, J | 1 |
| Huang, J | 1 |
| Zhang, J | 1 |
| Zhang, M | 1 |
| Lu, J | 1 |
| Zhou, S | 1 |
| Yuan, T | 1 |
| Shen, Z | 1 |
| Zheng, S | 1 |
| Guo, C | 1 |
| Kusi, M | 1 |
| Zand, M | 1 |
| Lin, LL | 1 |
| Chen, M | 1 |
| Lopez, A | 1 |
| Lin, CL | 1 |
| Wang, CM | 1 |
| Lucio, ND | 1 |
| Kirma, NB | 1 |
| Ruan, J | 1 |
| Huang, TH | 1 |
| Mitsuya, K | 1 |
| Zhao, M | 1 |
| Yao, P | 1 |
| Mao, Y | 1 |
| Wu, J | 1 |
| Wang, W | 1 |
| Geng, C | 1 |
| Cheng, J | 1 |
| Du, W | 2 |
| Jiang, P | 1 |
| Zhang, Z | 1 |
| Nathan, JA | 1 |
| Notarangelo, G | 1 |
| Spinelli, JB | 1 |
| Perez, EM | 1 |
| Baker, GJ | 1 |
| Kurmi, K | 1 |
| Elia, I | 1 |
| Stopka, SA | 1 |
| Baquer, G | 1 |
| Lin, JR | 1 |
| Golby, AJ | 1 |
| Joshi, S | 1 |
| Baron, HF | 1 |
| Drijvers, JM | 1 |
| Georgiev, P | 1 |
| Ringel, AE | 1 |
| Zaganjor, E | 1 |
| McBrayer, SK | 1 |
| Sorger, PK | 1 |
| Sharpe, AH | 1 |
| Wucherpfennig, KW | 1 |
| Santagata, S | 1 |
| Agar, NYR | 1 |
| Suvà, ML | 1 |
| Haigis, MC | 1 |
| Bernardo-Bermejo, S | 1 |
| Xue, J | 1 |
| Hoang, L | 1 |
| Billings, E | 1 |
| Webb, B | 1 |
| Honders, MW | 1 |
| Venneker, S | 1 |
| Heijs, B | 1 |
| Castro-Puyana, M | 1 |
| Marina, ML | 1 |
| van den Akker, EB | 1 |
| Griffioen, M | 1 |
| Siuzdak, G | 1 |
| Giera, M | 2 |
| Sánchez-López, E | 2 |
| Thamim, M | 2 |
| Agrahari, AK | 1 |
| Gupta, P | 1 |
| Thirumoorthy, K | 2 |
| Foskolou, IP | 2 |
| Bunse, L | 1 |
| Van den Bossche, J | 1 |
| Cunha, PP | 1 |
| Minogue, EA | 1 |
| Nicolet, BP | 1 |
| Guislain, A | 1 |
| Jorgensen, C | 1 |
| Kostidis, S | 1 |
| Zandhuis, ND | 1 |
| Barbieri, L | 1 |
| Bargiela, D | 1 |
| Nathanael, D | 1 |
| Tyrakis, PA | 1 |
| Palazon, A | 1 |
| Wolkers, MC | 1 |
| Johnson, RS | 1 |
| Wang, TX | 1 |
| Liang, JY | 1 |
| Zhang, C | 1 |
| Xiong, Y | 4 |
| Guan, KL | 3 |
| Yuan, HX | 1 |
| Kery, M | 1 |
| Papandreou, I | 1 |
| Wang, YP | 1 |
| Li, JT | 1 |
| Qu, J | 1 |
| Yin, M | 1 |
| Lei, QY | 1 |
| Liu, S | 1 |
| Cadoux-Hudson, T | 1 |
| Schofield, CJ | 3 |
| Yuan, BF | 2 |
| Collins, RRJ | 1 |
| Patel, K | 1 |
| Putnam, WC | 1 |
| Kapur, P | 1 |
| Rakheja, D | 1 |
| Gonsalves, WI | 1 |
| Ramakrishnan, V | 1 |
| Hitosugi, T | 1 |
| Ghosh, T | 1 |
| Jevremovic, D | 1 |
| Dutta, T | 1 |
| Sakrikar, D | 1 |
| Petterson, XM | 1 |
| Wellik, L | 1 |
| Kumar, SK | 1 |
| Nair, KS | 1 |
| Schaefer, IM | 1 |
| Hornick, JL | 1 |
| Bovée, JVMG | 1 |
| Park, J | 1 |
| Na, HK | 1 |
| Shon, HK | 1 |
| Son, HY | 1 |
| Huh, YM | 1 |
| Lee, SW | 1 |
| Lee, TG | 1 |
| Ye, D | 2 |
| Wenger, KJ | 1 |
| Hattingen, E | 1 |
| Harter, PN | 1 |
| Richter, C | 1 |
| Franz, K | 1 |
| Steinbach, JP | 1 |
| Bähr, O | 1 |
| Pilatus, U | 1 |
| Lee, S | 1 |
| Urman, A | 1 |
| Desai, P | 1 |
| Fan, B | 1 |
| Mellinghoff, IK | 1 |
| Wen, PY | 1 |
| Lowery, MA | 1 |
| Goyal, L | 1 |
| Tap, WD | 1 |
| Pandya, SS | 1 |
| Manyak, E | 1 |
| Jiang, L | 1 |
| Liu, G | 1 |
| Nimkar, T | 1 |
| Gliser, C | 1 |
| Prahl Judge, M | 1 |
| Agresta, S | 1 |
| Yang, H | 3 |
| Dai, D | 1 |
| Berger, RS | 1 |
| Ellmann, L | 1 |
| Reinders, J | 1 |
| Kreutz, M | 1 |
| Stempfl, T | 1 |
| Oefner, PJ | 1 |
| Dettmer, K | 1 |
| Tommasini-Ghelfi, S | 1 |
| Murnan, K | 1 |
| Kouri, FM | 1 |
| Mahajan, AS | 1 |
| May, JL | 1 |
| Stegh, AH | 1 |
| Krall, AS | 1 |
| Christofk, HR | 1 |
| Losman, JA | 1 |
| Kaelin, WG | 1 |
| Cairns, RA | 1 |
| Mak, TW | 1 |
| Guilhamon, P | 1 |
| Eskandarpour, M | 1 |
| Halai, D | 1 |
| Wilson, GA | 1 |
| Feber, A | 1 |
| Teschendorff, AE | 1 |
| Gomez, V | 1 |
| Hergovich, A | 1 |
| Tirabosco, R | 1 |
| Fernanda Amary, M | 1 |
| Baumhoer, D | 1 |
| Jundt, G | 1 |
| Ross, MT | 1 |
| Flanagan, AM | 1 |
| Beck, S | 1 |
| Guan, K | 1 |
| Menendez, JA | 1 |
| Alarcón, T | 1 |
| Joven, J | 1 |
| Ledford, H | 1 |
| Reitman, ZJ | 2 |
| Duncan, CG | 1 |
| Poteet, E | 1 |
| Winters, A | 1 |
| Yan, LJ | 1 |
| Gooden, DM | 1 |
| Spasojevic, I | 1 |
| Boros, LG | 1 |
| Yang, SH | 1 |
| Yan, H | 2 |
| Waterfall, JJ | 1 |
| Killian, JK | 1 |
| Meltzer, PS | 1 |
| Keum, YS | 1 |
| Choi, BY | 1 |
| Cheng, QY | 1 |
| Xiong, J | 1 |
| Huang, W | 1 |
| Ma, Q | 1 |
| Ci, W | 1 |
| Feng, YQ | 1 |
| Ricoult, SJ | 1 |
| Dibble, CC | 1 |
| Asara, JM | 1 |
| Manning, BD | 1 |
| Fujii, T | 1 |
| Khawaja, MR | 1 |
| DiNardo, CD | 1 |
| Atkins, JT | 1 |
| Janku, F | 1 |
| Sasaki, M | 1 |
| Xie, X | 1 |
| Baird, D | 1 |
| Bowen, K | 1 |
| Capka, V | 1 |
| Chen, J | 1 |
| Chenail, G | 1 |
| Cho, Y | 1 |
| Dooley, J | 1 |
| Farsidjani, A | 1 |
| Fortin, P | 1 |
| Kohls, D | 1 |
| Kulathila, R | 1 |
| Lin, F | 2 |
| McKay, D | 1 |
| Rodrigues, L | 1 |
| Sage, D | 1 |
| Touré, BB | 1 |
| van der Plas, S | 1 |
| Wright, K | 1 |
| Xu, M | 1 |
| Yin, H | 1 |
| Levell, J | 2 |
| Pagliarini, RA | 1 |
| Dang, L | 1 |
| White, DW | 1 |
| Gross, S | 1 |
| Bennett, BD | 1 |
| Bittinger, MA | 1 |
| Driggers, EM | 1 |
| Fantin, VR | 1 |
| Jang, HG | 1 |
| Jin, S | 1 |
| Keenan, MC | 1 |
| Marks, KM | 1 |
| Prins, RM | 1 |
| Ward, PS | 3 |
| Yen, KE | 1 |
| Liau, LM | 1 |
| Rabinowitz, JD | 1 |
| Cantley, LC | 1 |
| Thompson, CB | 3 |
| Vander Heiden, MG | 1 |
| Su, SM | 1 |
| Garber, K | 1 |
| Kranendijk, M | 1 |
| Struys, EA | 1 |
| van Schaftingen, E | 1 |
| Gibson, KM | 1 |
| Kanhai, WA | 1 |
| van der Knaap, MS | 1 |
| Amiel, J | 1 |
| Buist, NR | 1 |
| Das, AM | 1 |
| de Klerk, JB | 1 |
| Feigenbaum, AS | 1 |
| Grange, DK | 1 |
| Hofstede, FC | 1 |
| Holme, E | 1 |
| Kirk, EP | 1 |
| Korman, SH | 1 |
| Morava, E | 1 |
| Morris, A | 1 |
| Smeitink, J | 1 |
| Sukhai, RN | 1 |
| Vallance, H | 1 |
| Jakobs, C | 1 |
| Salomons, GS | 1 |
| Chowdhury, R | 1 |
| Yeoh, KK | 1 |
| Tian, YM | 1 |
| Hillringhaus, L | 1 |
| Bagg, EA | 1 |
| Rose, NR | 1 |
| Leung, IK | 1 |
| Li, XS | 1 |
| Woon, EC | 1 |
| Yang, M | 1 |
| McDonough, MA | 1 |
| King, ON | 1 |
| Clifton, IJ | 1 |
| Klose, RJ | 1 |
| Claridge, TD | 1 |
| Ratcliffe, PJ | 1 |
| Kawamura, A | 2 |
| Loenarz, C | 1 |
| Cross, JR | 2 |
| Lu, C | 2 |
| Weigert, O | 1 |
| Abel-Wahab, O | 1 |
| Levine, RL | 2 |
| Weinstock, DM | 1 |
| Sharp, KA | 1 |
| Grassian, AR | 1 |
| Barrett, R | 1 |
| Jiang, W | 1 |
| Korpal, M | 1 |
| Astley, H | 1 |
| Gitterman, D | 1 |
| Henley, T | 1 |
| Howes, R | 1 |
| Korn, JM | 1 |
| Pagliarini, R | 1 |
| Abdel-Wahab, O | 1 |
| Schwartz, GK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Long-term Observational Study in Patients With Monoclonal Gammopathy of Undetermined Significance[NCT05539079] | 2,000 participants (Anticipated) | Observational | 2023-09-06 | Recruiting | |||
| A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation[NCT02073994] | Phase 1 | 170 participants (Anticipated) | Interventional | 2014-03-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
19 reviews available for alpha-hydroxyglutarate and Neoplasms
| Article | Year |
|---|---|
Quantitative multiple fragment monitoring with enhanced in-source fragmentation/annotation mass spectrometry.
Topics: Chromatography, Liquid; Glutarates; Humans; Neoplasms; Tandem Mass Spectrometry | 2023 |
2-hydroxyglutarate rides the cancer-immunity cycle.
Topics: Glutarates; Humans; Ketoglutaric Acids; Mutation; Neoplasms; Stereoisomerism; Tumor Microenvironment | 2023 |
Emerging strategies to target cancer metabolism and improve radiation therapy outcomes.
Topics: Adaptation, Physiological; Animals; Ataxia Telangiectasia Mutated Proteins; DNA; DNA Damage; DNA Rep | 2020 |
Metabolite sensing and signaling in cancer.
Topics: Animals; Epigenesis, Genetic; Glutarates; Humans; Metabolic Networks and Pathways; Metabolome; Metab | 2020 |
Isocitrate dehydrogenase variants in cancer - Cellular consequences and therapeutic opportunities.
Topics: Animals; Enzyme Inhibitors; Glutarates; Humans; Isocitrate Dehydrogenase; Ketoglutaric Acids; Models | 2020 |
Oncometabolites: A New Paradigm for Oncology, Metabolism, and the Clinical Laboratory.
Topics: Animals; Clinical Laboratory Services; Fumarates; Glutarates; Humans; Metabolic Networks and Pathway | 2017 |
The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms.
Topics: Animals; Fumarate Hydratase; Fumarates; Glutarates; Humans; Isocitrate Dehydrogenase; Mixed Function | 2018 |
Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates.
Topics: Animals; Glutarates; Humans; Isocitrate Dehydrogenase; Molecular Targeted Therapy; Mutation; Neoplas | 2018 |
Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications.
Topics: Antineoplastic Agents; Citric Acid Cycle; Epigenesis, Genetic; Glutarates; Humans; Isocitrate Dehydr | 2019 |
Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease.
Topics: Allosteric Site; Animals; Catalytic Domain; Citric Acid Cycle; Cytoplasm; DNA Methylation; Epigenesi | 2019 |
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.
Topics: Animals; Catalysis; Glutarates; Humans; Isocitrate Dehydrogenase; Mutation; Neoplasms; Oncogenes | 2013 |
Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities.
Topics: Animals; Arginine; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Knock-In Techni | 2013 |
Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.
Topics: Bile Duct Neoplasms; Bone Neoplasms; Central Nervous System Neoplasms; Cholangiocarcinoma; Chondrosa | 2013 |
Metabolic alteration in tumorigenesis.
Topics: Carcinogenesis; Cell Proliferation; Epigenesis, Genetic; Fumarate Hydratase; Glutarates; Humans; Iso | 2013 |
The role of mutation of metabolism-related genes in genomic hypermethylation.
Topics: Dioxygenases; DNA Methylation; Fumarate Hydratase; Genome, Human; Glutarates; Humans; Isocitrate Deh | 2014 |
Isocitrate dehydrogenase mutations: new opportunities for translational research.
Topics: Arginine; Enzyme Inhibitors; Glutarates; Humans; Isocitrate Dehydrogenase; Isoenzymes; Mutation, Mis | 2015 |
Targeting isocitrate dehydrogenase (IDH) in cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cell Differe | 2016 |
Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.
Topics: Animals; Arginine; Brain Neoplasms; Codon; Gene Expression Regulation, Enzymologic; Gene Expression | 2010 |
IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.
Topics: Cell Differentiation; Cell Transformation, Neoplastic; DNA Methylation; Glutarates; Histone Demethyl | 2012 |
1 trial available for alpha-hydroxyglutarate and Neoplasms
| Article | Year |
|---|---|
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relations | 2020 |
33 other studies available for alpha-hydroxyglutarate and Neoplasms
| Article | Year |
|---|---|
Cancer-associated IDH mutations induce Glut1 expression and glucose metabolic disorders through a PI3K/Akt/mTORC1-Hif1α axis.
Topics: Animals; Cell Proliferation; Fibroblasts; Gene Expression Regulation, Neoplastic; Glucose; Glucose M | 2021 |
A D-2-hydroxyglutarate biosensor based on specific transcriptional regulator DhdR.
Topics: Achromobacter denitrificans; Alcohol Oxidoreductases; Bacteria; Biosensing Techniques; Gene Expressi | 2021 |
D2HGDH-mediated D2HG catabolism enhances the anti-tumor activities of CAR-T cells in an immunosuppressive microenvironment.
Topics: Alcohol Oxidoreductases; Animals; Cell Line, Tumor; Cell Proliferation; Cytokines; Glutarates; Human | 2022 |
2-Hydroxyglutarate destabilizes chromatin regulatory landscape and lineage fidelity to promote cellular heterogeneity.
Topics: Alcohol Oxidoreductases; Ascorbic Acid; Cell Differentiation; Cell Line, Tumor; Chromatin; DNA Repai | 2022 |
Malic enzyme 2 maintains protein stability of mutant p53 through 2-hydroxyglutarate.
Topics: Carcinogenesis; Glutarates; Humans; Malate Dehydrogenase; Neoplasms; Protein Stability; Tumor Suppre | 2022 |
Malic enzyme 2 as a therapeutic target for cancer: comments on 'Malic enzyme 2 maintains protein stability of mutant p53 through 2-hydroxyglutarate'.
Topics: Glutarates; Humans; Liver; Malate Dehydrogenase; Neoplasms; Protein Stability; Tumor Suppressor Prot | 2022 |
Metabolite-driven antitumor immunity.
Topics: Animals; CD8-Positive T-Lymphocytes; Glutarates; Glycolysis; Humans; Isocitrate Dehydrogenase; Mice; | 2022 |
Oncometabolite d-2HG alters T cell metabolism to impair CD8
Topics: Animals; Carcinogenesis; CD8-Positive T-Lymphocytes; Gain of Function Mutation; Glutarates; Humans; | 2022 |
Rational Computational Approaches in Drug Discovery: Potential Inhibitors for Allosteric Regulation of Mutant Isocitrate Dehydrogenase-1 Enzyme in Cancers.
Topics: Allosteric Regulation; Drug Discovery; Enzyme Inhibitors; Glutarates; Humans; Isocitrate Dehydrogena | 2023 |
The two enantiomers of 2-hydroxyglutarate differentially regulate cytotoxic T cell function.
Topics: CD8-Positive T-Lymphocytes; Glutarates; Humans; Isocitrate Dehydrogenase; Neoplasms; T-Lymphocytes, | 2023 |
The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis.
Topics: Alleles; Cell Line, Tumor; Ferroptosis; Glutarates; Humans; Iron; Ischemia; Isocitrate Dehydrogenase | 2019 |
Chiral discrimination in a mutated IDH enzymatic reaction in cancer: a computational perspective.
Topics: Brain Neoplasms; Catalytic Domain; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Ketoglutari | 2020 |
Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate.
Topics: Glutarates; Humans; Isocitrate Dehydrogenase; Mutation; Neoplasms | 2021 |
Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Citric Acid Cycle; Disease Progression; DNA-Binding Proteins; G | 2018 |
TOF-SIMS analysis of an isocitrate dehydrogenase 1 mutation-associated oncometabolite in cancer cells.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Glutarates; Humans; Isocitrate Dehydrogenase; Models, Biologica | 2018 |
Fitting algorithms and baseline correction influence the results of non-invasive in vivo quantitation of 2-hydroxyglutarate with
Topics: Adult; Aged; Algorithms; Female; Glutarates; Humans; Male; Middle Aged; Mutation; Neoplasms; Phantom | 2019 |
Degradation of D-2-hydroxyglutarate in the presence of isocitrate dehydrogenase mutations.
Topics: Alcohol Oxidoreductases; Cell Line, Tumor; Chromatography, Liquid; Glioma; Glutarates; HCT116 Cells; | 2019 |
Cancer: A metabolic metamorphosis.
Topics: Epigenesis, Genetic; Glutarates; Humans; Isocitrate Dehydrogenase; Mutant Proteins; Neoplasms | 2013 |
Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites.
Topics: Aging; Cell Hypoxia; Cellular Reprogramming; Epigenesis, Genetic; Fumarate Hydratase; Fumarates; Glu | 2014 |
Metabolic quirks yield tumour hope.
Topics: Animals; Antineoplastic Agents; Citric Acid Cycle; Clinical Trials as Topic; Glucose; Glutarates; Hu | 2014 |
Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia.
Topics: Cell Hypoxia; Cell Line, Tumor; Glutarates; Glycolysis; HCT116 Cells; Humans; Isocitrate Dehydrogena | 2014 |
Sensitive Determination of Onco-metabolites of D- and L-2-hydroxyglutarate Enantiomers by Chiral Derivatization Combined with Liquid Chromatography/Mass Spectrometry Analysis.
Topics: Carcinoma, Renal Cell; Chromatography, Liquid; Glutarates; Humans; Metabolome; Metabolomics; Neoplas | 2015 |
Sterol Regulatory Element Binding Protein Regulates the Expression and Metabolic Functions of Wild-Type and Oncogenic IDH1.
Topics: Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glucose; Glutarates; Humans; Isocitrate De | 2016 |
[Epigenetic alterations and biological phenomena caused by mutation in an IDH gene].
Topics: Animals; Biological Phenomena; Epigenesis, Genetic; Glutarates; Humans; Isocitrate Dehydrogenase; Mu | 2016 |
Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity.
Topics: Allosteric Regulation; Allosteric Site; Crystallography, X-Ray; Enzyme Inhibitors; Glutarates; Human | 2017 |
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Topics: Age Factors; Glutarates; Humans; Isocitrate Dehydrogenase; Mutation; Neoplasms | 2010 |
Oncometabolite? IDH1 discoveries raise possibility of new metabolism targets in brain cancers and leukemia.
Topics: Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppre | 2010 |
IDH2 mutations in patients with D-2-hydroxyglutaric aciduria.
Topics: Adolescent; Brain Diseases, Metabolic, Inborn; Brain Neoplasms; Child; Child, Preschool; Female; Ger | 2010 |
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.
Topics: Cell Line, Tumor; Crystallography; Glutarates; Histone Demethylases; Humans; Inhibitory Concentratio | 2011 |
Mutations to metabolic enzymes in cancer herald a need to unify genetics and biochemistry.
Topics: Citric Acid Cycle; Enzyme Activation; Gene Expression Regulation, Enzymologic; Gene Expression Regul | 2011 |
Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.
Topics: Cell Line, Tumor; Cytosol; Glutarates; Humans; Isocitrate Dehydrogenase; Mitochondria; Mutation; Neo | 2012 |
Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT).
Topics: Amino Acid Substitution; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Gene Expression Regula | 2012 |
The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
Topics: 3T3-L1 Cells; Alleles; Amino Acid Substitution; Animals; Cell Line, Tumor; Glutarates; Humans; Isoci | 2013 |